Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 282

1.

Diabetes and peripheral vascular disease.

Huysman E, Mathieu C.

Acta Chir Belg. 2009 Oct;109(5):587-94. Review.

PMID:
19994800
2.

Multifactorial aspects of the treatment of the type II diabetic patient.

Colwell JA.

Metabolism. 1997 Dec;46(12 Suppl 1):1-4. Review.

PMID:
9439550
3.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
4.

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P.

Am Heart J. 2006 Jul;152(1):27-38. Review.

PMID:
16824829
6.

[Treatment of diabetes in metabolic syndrome].

Pelikánova T.

Vnitr Lek. 2009 Jul-Aug;55(7-8):637-45. Review. Czech.

PMID:
19731868
7.

Peripheral arterial disease in patients with diabetes.

Marso SP, Hiatt WR.

J Am Coll Cardiol. 2006 Mar 7;47(5):921-9. Epub 2006 Feb 9. Review.

8.
9.

Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study.

Pedersen O, Gaede P.

Metabolism. 2003 Aug;52(8 Suppl 1):19-23. Review.

PMID:
12939735
10.

[Glycemic control and cardiovascular benefit: What do we know today?].

Hanefeld M, Schönauer M, Forst T.

Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. doi: 10.1055/s-0029-1244853. Epub 2010 Feb 9. Review. German.

PMID:
20146161
11.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
12.

[Epidemiology of cardio-vascular complications of diabetes].

Grimaldi A, Heurtier A.

Diabetes Metab. 1999 Jun;25 Suppl 3:12-20. Review. French.

PMID:
10421988
13.

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.

Krentz AJ.

Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. Review.

PMID:
14984018
14.

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.

Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, Henderson W; VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2..

J Diabetes Complications. 2003 Nov-Dec;17(6):314-22.

PMID:
14583175
15.
16.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
17.

Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P; ACCORD Study Group..

Am J Cardiol. 2007 Jun 18;99(12A):34i-43i. Epub 2007 Apr 19.

PMID:
17599423
18.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
19.

Importance of glucose control.

Edelman SV.

Med Clin North Am. 1998 Jul;82(4):665-87. Review.

PMID:
9706116
20.

Diabetes and cardiovascular disease: the role of glycemic control.

Cheng AY, Leiter LA.

Curr Diab Rep. 2009 Feb;9(1):65-72.

PMID:
19192427

Supplemental Content

Support Center